Analysts Anticipate CRISPR Therapeutics AG (NASDAQ:CRSP) to Post -$2.23 EPS

Equities research analysts predict that CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) will report earnings of ($2.23) per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for CRISPR Therapeutics’ earnings, with estimates ranging from ($2.48) to ($1.92). CRISPR Therapeutics reported earnings of $9.44 per share during the same quarter last year, which would indicate a negative year over year growth rate of 123.6%. The firm is scheduled to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that CRISPR Therapeutics will report full year earnings of ($8.97) per share for the current fiscal year, with EPS estimates ranging from ($10.41) to ($7.77). For the next financial year, analysts forecast that the company will report earnings of ($7.62) per share, with EPS estimates ranging from ($13.32) to ($3.29). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last issued its quarterly earnings data on Monday, May 9th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.94) by ($0.38). The company had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $2.45 million. CRISPR Therapeutics had a return on equity of 12.77% and a net margin of 34.04%. The business’s revenue for the quarter was up 74.4% compared to the same quarter last year. During the same period last year, the company earned ($1.51) earnings per share.

CRSP has been the topic of a number of analyst reports. The Goldman Sachs Group decreased their price objective on CRISPR Therapeutics from $179.00 to $87.00 and set a “neutral” rating on the stock in a research note on Thursday, February 17th. StockNews.com assumed coverage on CRISPR Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. Royal Bank of Canada dropped their price objective on CRISPR Therapeutics from $95.00 to $85.00 in a report on Tuesday, May 10th. Needham & Company LLC cut their target price on shares of CRISPR Therapeutics from $170.00 to $122.00 in a research note on Friday, May 13th. Finally, SVB Leerink lowered their target price on CRISPR Therapeutics from $126.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, February 16th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $121.60.

NASDAQ:CRSP traded down $2.23 during trading on Friday, reaching $54.26. The company’s stock had a trading volume of 55,945 shares, compared to its average volume of 1,480,554. CRISPR Therapeutics has a 12 month low of $42.51 and a 12 month high of $169.76. The firm has a 50 day moving average of $58.73 and a 200-day moving average of $66.97. The firm has a market cap of $4.20 billion, a price-to-earnings ratio of 15.22 and a beta of 2.05.

Several large investors have recently added to or reduced their stakes in the company. Intellectus Partners LLC increased its position in CRISPR Therapeutics by 1.1% during the 3rd quarter. Intellectus Partners LLC now owns 11,170 shares of the company’s stock valued at $1,250,000 after buying an additional 125 shares in the last quarter. Wagner Wealth Management LLC lifted its holdings in CRISPR Therapeutics by 30.0% in the third quarter. Wagner Wealth Management LLC now owns 650 shares of the company’s stock valued at $59,000 after acquiring an additional 150 shares during the period. Antonetti Capital Management LLC raised its holdings in CRISPR Therapeutics by 16.1% in the 4th quarter. Antonetti Capital Management LLC now owns 1,190 shares of the company’s stock worth $76,000 after purchasing an additional 165 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its stake in CRISPR Therapeutics by 16.8% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 1,238 shares of the company’s stock worth $94,000 after purchasing an additional 178 shares during the last quarter. Finally, Avantax Advisory Services Inc. lifted its position in CRISPR Therapeutics by 4.0% during the fourth quarter. Avantax Advisory Services Inc. now owns 4,598 shares of the company’s stock worth $348,000 after buying an additional 178 shares in the last quarter. Institutional investors and hedge funds own 56.12% of the company’s stock.

About CRISPR Therapeutics (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Further Reading